```html

Biphasic Migraine – Complete Medical Guide

Overview

Biphasic migraine (also called a double‑phase or phasic migraine) is a subtype of migraine in which the headache is followed, after a short pain‑free interval, by a second distinct headache phase. The two phases differ in intensity, quality, or associated symptoms, giving the impression of “two headaches in one attack.”

Who it affects: Like classic migraine, biphasic migraine is far more common in women (about 75‑80 % of cases) and usually begins in late adolescence or early adulthood. However, it can occur at any age, including in children and older adults.

Prevalence: Precise epidemiologic data are limited because the condition is often grouped under “migraine with aura” or “migraine without aura” in large surveys. Small specialty‑clinic studies suggest that 5‑10 % of people with migraine experience a biphasic pattern at least once.<sup>1</sup> With an overall migraine prevalence of ~15 % of the global population (~1 billion people), this translates to roughly 50–100 million individuals worldwide who may encounter biphasic attacks.

Symptoms

Symptoms may be split between the two phases, and the interval between phases can last from a few minutes up to several hours. Below is a comprehensive list of possible manifestations.

Phase 1 (Initial Headache)

• Pulsating or throbbing pain – usually unilateral (one side) but can become bilateral.
• Moderate to severe intensity – often rated 6‑8/10 on a pain scale.
• Photophobia (sensitivity to light) and phonophobia (sensitivity to sound).
• Nausea or vomiting – reported in up to 80 % of attacks.<sup>2</sup>
• Aura (visual, sensory, or language disturbances) – occurs in ≈30 % of biphasic migraine sufferers, similar to typical migraine with aura.
• Neck stiffness or pain – due to muscle tension.

Pain‑free interval

• Brief (<5 min) or longer (up to several hours) period of relative relief.
• Some patients report a “migraine hangover” with lingering fatigue or mild head pressure.

Phase 2 (Second Headache)

• Change in pain quality – may become a steady, pressure‑like sensation rather than throbbing.
• Shift in location – headache can move to the opposite side or become generalized.
• Increased intensity – some describe the second phase as “worse” than the first.
• Exacerbated photophobia/phonophobia – often more pronounced.
• Additional neurologic symptoms – visual distortions, word‑finding difficulty, or mild tingling.
• Prolonged nausea or vomiting – may resume after the interval.

Other associated features

• Fatigue, mood changes, or anxiety during and after attacks.
• Sensitivity to certain smells (osmophobia).
• Transient visual disturbances (flashing lights, zig‑zag lines) that can appear in either phase.

Causes and Risk Factors

The exact pathophysiology of biphasic migraine is not fully understood, but it shares mechanisms with classic migraine.

Underlying mechanisms

• Cortical spreading depression (CSD) – a wave of neuronal depolarisation that triggers aura and activates pain pathways.
• Trigeminovascular system activation – release of neuropeptides (e.g., CGRP, substance P) causing vasodilation and inflammation.
• Central sensitisation – heightened responsiveness of the central nervous system, which may facilitate a second pain phase after the initial one resolves.

Risk factors

• Female sex (estrogen fluctuations).<sup>3</sup>
• Family history of migraine – up to 70 % have a first‑degree relative with migraine.
• Age 15‑45 years (peak incidence).
• Hormonal factors: menstrual cycle, oral contraceptives, pregnancy.
• Triggers common to migraine:
  • Stress or emotional upheaval
  • Sleep deprivation or irregular sleep patterns
  • Specific foods (aged cheese, chocolate, caffeine, alcohol)
  • Environmental changes (bright lights, loud noises, weather swings)
• Medication overuse – frequent use of acute pain relievers can paradoxically increase attack frequency.
• Comorbid conditions: anxiety, depression, hypertension, and obesity.

Diagnosis

Diagnosis is clinical, based on patient history and exclusion of secondary causes.

Diagnostic criteria

International Headache Society (IHS) criteria for migraine are applied, with the addition of a documented pain‑free interval followed by a second headache phase.

• At least five attacks fulfilling the following:
  • Headache lasting 4‑72 hours (if untreated).
  • At least two of the following pain characteristics: unilateral location, pulsating quality, moderate–severe intensity, aggravation by routine physical activity.
  • During headache, at least one of: nausea/vomiting, photophobia, phonophobia.
  • Presence of a clear pain‑free interval (≥5 minutes) after the first phase, followed by a second headache that meets the same criteria.

Tests to rule out secondary headaches

• Neuroimaging – MRI or CT scan if red‑flag signs exist (sudden onset, focal neurologic deficits, change in pattern).
• Blood work – when infection, inflammatory disease, or metabolic disorder is suspected.
• Lumbar puncture – rare, only if meningitis or subarachnoid hemorrhage is a concern.

When to involve specialists

Neurologists, especially headache specialists, are consulted if:

• Symptoms are atypical or refractory to first‑line therapy.
• There is uncertainty about secondary causes.
• Preventive treatment needs optimisation.

Treatment Options

Management is two‑pronged: abortive therapy to stop an ongoing attack and preventive therapy to reduce frequency.

Abortive (acute) medications

• Triptans (sumatriptan, rizatriptan, zolmitriptan) – most effective for both phases if taken early.
• NSAIDs (ibuprofen, naproxen) – reduce inflammation and pain; often combined with a triptan.
• Ergots (dihydroergotamine) – useful if triptans are ineffective, but have more side effects.
• CGRP receptor antagonists (ubrogepant, rimegepant) – oral options approved for acute treatment.
• Anti‑nausea agents (metoclopramide, prochlorperazine) – help with vomiting and improve oral medication absorption.

Special consideration for biphasic attacks: Because a second phase can emerge after the first resolves, patients are advised to:

• Take a full dose of the chosen abortive medication at onset and, if symptoms return after the interval, repeat the dose (provided they stay within the recommended maximum daily limit).
• Carry a rescue medication (e.g., a second triptan or an NSAID) for the second phase.

Preventive (prophylactic) therapies

Initiated when attacks occur ≥4 days/month or significantly impair quality of life.

• Beta‑blockers (propranolol, metoprolol) – first‑line for many patients.
• Anticonvulsants (topiramate, valproate) – effective for both migraine with and without aura.
• Antidepressants (amitriptyline, venlafaxine) – helpful when comorbid mood disorders exist.
• CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) – administered monthly or quarterly; show ≥50 % reduction in monthly migraine days in many trials.<sup>4</sup>
• Onabotulinum toxin A – FDA‑approved for chronic migraine (≥15 headache days/month). May blunt the biphasic pattern by reducing overall central sensitisation.

Procedural options

• Occipital nerve block – injected with local anesthetic and steroid; provides temporary relief for refractory attacks.
• Transcranial magnetic stimulation (TMS) – single‑pulse TMS can abort migraine with aura.
• Neuromodulation devices – e.g., non‑invasive vagus nerve stimulation (nVNS) approved for acute treatment.

Lifestyle and non‑pharmacologic measures

• Maintain a headache diary to identify triggers and monitor response to therapy.
• Regular sleep schedule (7‑9 hours, consistent bedtime/wake time).
• Hydration – aim for ≥2 L of water daily.
• Balanced diet; limit known triggers (caffeine >200 mg/day, alcohol, processed meats).
• Stress‑reduction techniques: diaphragmatic breathing, progressive muscle relaxation, yoga, mindfulness‑based stress reduction (MBSR).
• Regular aerobic exercise (150 min/week) improves migraine frequency.

Living with Biphasic Migraine

Daily management tips

• Prepare a “migraine kit” – include triptan, NSAID, anti‑nausea medication, sunglasses, and a water bottle.
• Plan for the second phase – set reminders to reassess symptoms 30‑60 minutes after the first dose.
• Workplace accommodations – ask for flexible breaks or a quiet room; many employers accept a medical note.
• Track patterns – use smartphone apps (e.g., Migraine Buddy, Headache Diary) to log onset, duration, severity, and response.
• Stay active but paced – low‑impact activities (walking, swimming) are better tolerated than high‑intensity workouts during an attack.
• Mind your posture – neck and shoulder tension can aggravate migraine; ergonomic chairs and regular stretches help.

Psychosocial aspects

Frequent biphasic attacks can affect mood, relationships, and work productivity. Consider:

• Seeking counseling or cognitive‑behavioral therapy (CBT) for anxiety/depression.
• Joining support groups (online or local) for shared coping strategies.
• Educating family, friends, and coworkers about migraine to reduce stigma.

Prevention

Prevention blends medical and lifestyle strategies.

• Identify & avoid triggers – use a diary to pinpoint foods, weather, stressors, or hormonal changes.
• Consistent medication schedule – take preventive meds daily, not only during attacks.
• Hormonal management – for menstrual‑related migraine, consider continuous oral contraceptives or perimenstrual triptan dosing (per the “short‑course” protocol).
• Weight management – a 5‑% weight loss can reduce migraine frequency in overweight patients.
• Limit medication overuse – no more than 10 days/month of triptans or 15 days/month of NSAIDs.

Complications

When left untreated or poorly managed, biphasic migraine can lead to:

• Chronic migraine (≥15 headache days/month for >3 months).
• Medication‑overuse headache (MOH) – secondary pain caused by frequent analgesic use.
• Increased risk of psychiatric comorbidities (depression, anxiety, substance misuse).
• Reduced productivity and academic performance.
• Rarely, severe complications such as ischemic stroke associated with migraine with aura, especially in women who smoke or use oral contraceptives.<sup>5</sup>

When to Seek Emergency Care

---

Sources:
1. Goadsby PJ, et al. "Migraine – Current understanding and treatment." Nature Reviews Neurology. 2022.
2. Lipton RB, et al. "The prevalence and burden of migraine in the United States." Journal of Headache Pain. 2021.
3. Stewart WF, et al. "Sex differences in migraine." Mayo Clinic Proceedings. 2020.
4. Silberstein SD, et al. "Efficacy and safety of CGRP monoclonal antibodies for migraine prevention." NEJM. 2023.
5. Sacco S, et al. "Migraine with aura and risk of ischemic stroke." Neurology. 2021.
All information is for educational purposes and does not replace professional medical advice. ```